Contact
Please use this form to send email to PR contact of this press release:
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
TO:
Please use this form to send email to PR contact of this press release:
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
TO: